Our results not only elucidate the metabolic mechanism underlying the development of acquired resistance to EGFR TKIs but also indicate that targeting PKCδ/SGLT1 in combination with EGFR TKIs may benefit NSCLC patients. This evidence concerns the gene PRKCD and non-small cell lung carcinoma.